Tags

Type your tag names separated by a space and hit enter

The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
Lung Cancer. 2015 Jun; 88(3):325-31.LC

Abstract

OBJECTIVES

Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency of FGFR1 amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance of FGFR1 amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies.

MATERIALS AND METHODS

Tumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using an FGFR1 FISH assay with a probe that hybridized to chromosome region 8p12-8p11.23 (Abbott Molecular, Abbott Park, IL).

RESULTS AND CONCLUSION

FGFR1 amplification was detected in three patients (1.9%) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR]=7.1; 95% confidence interval [CI]=2.0-25.4; P=0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and without FGFR1 amplification, respectively (P=0.37). Although FGFR1 amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply that FGFR1 may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial.

Authors+Show Affiliations

Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.Department of Pathology, Dongguk University College of Medicine, Dongguk University Ilsan Hospital, Goyang, South Korea; Department of Medicine, Graduate School of Yonsei University, South Korea.Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, South Korea.Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, South Korea.Department of Biostatistics, Yonsei University College of Medicine, Seoul, South Korea.Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: cbc1971@yuhs.ac.Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: shimhs@yuhs.ac.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25819384

Citation

Park, Ji Soo, et al. "The Frequency and Impact of FGFR1 Amplification On Clinical Outcomes in Korean Patients With Small Cell Lung Cancer." Lung Cancer (Amsterdam, Netherlands), vol. 88, no. 3, 2015, pp. 325-31.
Park JS, Lee JS, Kim EY, et al. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. Lung Cancer. 2015;88(3):325-31.
Park, J. S., Lee, J. S., Kim, E. Y., Jung, J. Y., Kim, S. K., Chang, J., Kim, D. J., Lee, C. Y., Jung, I., Kim, J. H., Kim, H. R., Moon, Y. W., Kim, H. S., Cho, B. C., & Shim, H. S. (2015). The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 88(3), 325-31. https://doi.org/10.1016/j.lungcan.2015.03.002
Park JS, et al. The Frequency and Impact of FGFR1 Amplification On Clinical Outcomes in Korean Patients With Small Cell Lung Cancer. Lung Cancer. 2015;88(3):325-31. PubMed PMID: 25819384.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. AU - Park,Ji Soo, AU - Lee,Jae-Seok, AU - Kim,Eun Young, AU - Jung,Ji Ye, AU - Kim,Se Kyu, AU - Chang,Joon, AU - Kim,Dae Joon, AU - Lee,Chang Young, AU - Jung,Inkyung, AU - Kim,Joo Hang, AU - Kim,Hye Ryun, AU - Moon,Yong Wha, AU - Kim,Hyo Song, AU - Cho,Byoung Chul, AU - Shim,Hyo Sup, Y1 - 2015/03/09/ PY - 2014/11/05/received PY - 2015/01/22/revised PY - 2015/03/01/accepted PY - 2015/3/31/entrez PY - 2015/3/31/pubmed PY - 2016/2/4/medline KW - Amplification KW - Biomarker KW - FGFR1 KW - FISH KW - Prognosis KW - Small cell lung cancer SP - 325 EP - 31 JF - Lung cancer (Amsterdam, Netherlands) JO - Lung Cancer VL - 88 IS - 3 N2 - OBJECTIVES: Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency of FGFR1 amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance of FGFR1 amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies. MATERIALS AND METHODS: Tumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using an FGFR1 FISH assay with a probe that hybridized to chromosome region 8p12-8p11.23 (Abbott Molecular, Abbott Park, IL). RESULTS AND CONCLUSION: FGFR1 amplification was detected in three patients (1.9%) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR]=7.1; 95% confidence interval [CI]=2.0-25.4; P=0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and without FGFR1 amplification, respectively (P=0.37). Although FGFR1 amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply that FGFR1 may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial. SN - 1872-8332 UR - https://www.unboundmedicine.com/medline/citation/25819384/The_frequency_and_impact_of_FGFR1_amplification_on_clinical_outcomes_in_Korean_patients_with_small_cell_lung_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0169-5002(15)00154-3 DB - PRIME DP - Unbound Medicine ER -